TNC and brain neoplasm: Several successful phase I and phase II trials in brain tumor patients with anti-tenascin mAbs BC-2, BC-4, and 81C6 labeled with the β-emitters, 131I and 90Y, and the α-emitter, 211At, demonstrated the therapeutic potential of RIT [145].